Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia

Blood

Volumn 125, Issue 19, 2015, Pages 2985-2994

  Kühnl, Andrea ^a,b   Valk, Peter J M ^c   Sanders, Mathijs A ^c   Ivey, Adam ^a   Hills, Robert K ^d   Mills, Ken I ^e   Gale, Rosemary E ^f   Kaiser, Martin F ^b   Dillon, Richard ^a   Joannides, Melanie ^a   Gilkes, Amanda ^d   Haferlach, Torsten ^g   Schnittger, Susanne ^g   Duprez, Estelle ^h   Linch, David C ^f   Delwel, Ruud ^c   Löwenberg, Bob ^c   Baldus, Claudia D ^b   Solomon, Ellen ^a   Burnett, Alan K ^d   Grimwade, David ^a,i   more..

^a KING'S COLLEGE LONDON   (United Kingdom)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^e QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^h AIX MARSEILLE UNIVERSITY   (France)

ⁱ GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AURKA PROTEIN; BAALC PROTEIN; BETA CATENIN; BUB1 PROTEIN; CCNB1 PROTEIN; CCNB2 PROTEIN; CDK1 PROTEIN; CELL CYCLE PROTEIN 20; CXXC5 PROTEIN; CYCLIN A2; DLGAP5 PROTEIN; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; EVI1 PROTEIN; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; KIF23 PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; NEK2 PROTEIN; NUCLEOPHOSMIN; PROTEIN; PROTEIN BCL 6; PROTEIN P53; SURVIVIN; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTION FACTOR RUNX1; UBE2C PROTEIN; UNCLASSIFIED DRUG; WT1 PROTEIN; ZINC FINGER PROTEIN; CARRIER PROTEIN; CXXC5 PROTEIN, HUMAN; MESSENGER RNA; TUMOR MARKER; WNT PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL CYCLE ARREST; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA DAMAGE; DNA SEQUENCE; DOWN REGULATION; EVENT FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; HL 60 CELL LINE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; K562 CELL LINE; LEUKEMOGENESIS; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METHYLATION; MTT ASSAY; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; PYROSEQUENCING; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WNT SIGNALING PATHWAY; ANTAGONISTS AND INHIBITORS; CELL CYCLE; COHORT ANALYSIS; DNA METHYLATION; DNA MICROARRAY; ENZYME IMMUNOASSAY; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR CELL CULTURE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOMARKERS, TUMOR; CARRIER PROTEINS; CELL CYCLE; COHORT STUDIES; DNA METHYLATION; DOWN-REGULATION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOENZYME TECHNIQUES; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR CELLS, CULTURED; WNT PROTEINS; YOUNG ADULT;

EID: 84929166801     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-12-613703     Document Type: Article

References (50)

1. Burnett A, Wetzler M, Löwenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29(5):487-494.
2. Burnett AK, Milligan D, Goldstone A, et al United Kingdom National Cancer Research Institute Haematological Oncology Study Group. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol. 2009;145(3):318-332.
3. Zhang M, Wang R, Wang Y, et al. The CXXC finger 5 protein is required for DNA damageinduced p53 activation. Sci China C Life Sci. 2009;52(6):528-538.
4. Kim MS, Yoon SK, Bollig F, et al. A novel Wilms tumor 1 (WT1) target gene negatively regulates the WNT signaling pathway. J Biol Chem. 2010; 285(19):14585-14593.
5. Andersson T, Södersten E, Duckworth JK, et al. CXXC5 is a novel BMP4-regulated modulator of Wnt signaling in neural stem cells. J Biol Chem. 2009;284(6):3672-3681.
6. Wang Y, Krivtsov AV, Sinha AU, et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science. 2010;327(5973):1650-1653.
7. Simon M, Grandage VL, Linch DC, Khwaja A. Constitutive activation of the Wnt/beta-catenin signalling pathway in acute myeloid leukaemia. Oncogene. 2005;24(14):2410-2420.
8. Müller-Tidow C, Steffen B, Cauvet T, et al. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol. 2004;24(7): 2890-2904.
9. Ayton PM, Cleary ML. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene. 2001;20(40):5695-5707.
10. Mizuno S, Chijiwa T, Okamura T, et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood. 2001; 97(5):1172-1179.
11. Trowbridge JJ, Sinha AU, Zhu N, Li M, Armstrong SA, Orkin SH. Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains. Genes Dev. 2012;26(4):344-349.
12. Dolnik A, Engelmann JC, Scharfenberger- Schmeer M, et al. Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing. Blood. 2012;120(18): e83-e92.
13. Lorsbach RB, Moore J, Mathew S, Raimondi SC, Mukatira ST, Downing JR. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia. 2003;17(3):637-641.
14. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424-2433.
15. Abdel-Wahab O, Mullally A, Hedvat C, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009;114(1):144-147.
16. Kojima T, Shimazui T, Hinotsu S, et al. Decreased expression of CXXC4 promotes a malignant phenotype in renal cell carcinoma by activating Wnt signaling. Oncogene. 2009;28(2):297-305.
17. Treppendahl M, Mollgard L, Hellstrom-Lindberg E, Cloos P, Gronbaek K. Downregulation but lack of promoter hypermethylation or somatic mutations of the potential tumor suppressor CXXC5 in MDS and AML with deletion 5q. Eur J Haematol. 2013; 90(3):259-260.
18. Murati A, Gervais C, Carbuccia N, et al Groupe Francophone de Cytogénétique Hématologique. Genome profiling of acute myelomonocytic leukemia: alteration of the MYB locus in MYST3- linked cases. Leukemia. 2009;23(1):85-94.
19. Gelsi-Boyer V, Trouplin V, AdélaïdeJ,etal. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2009; 145(6):788-800.
20. Pendino F, Nguyen E, Jonassen I, et al. Functional involvement of RINF, retinoid-inducible nuclear factor (CXXC5), in normal and tumoral human myelopoiesis. Blood. 2009;113(14): 3172-3181.
21. Astori A, Fredly H, Aloysius TA, et al. CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia. Oncotarget. 2013;4(9): 1438-1448.
22. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004; 350(16):1617-1628.
23. Verhaak RG, Wouters BJ, Erpelinck CA, et al. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica. 2009;94(1):131-134.
24. Haferlach T, Kohlmann A, Wieczorek L, et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol. 2010;28(15): 2529-2537.
25. Grimwade D, Jovanovic JV, Hills RK, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol. 2009;27(22):3650-3658.
26. Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe Against Cancer program. Leukemia. 2003;17(12):2474-2486.
27. Owen C, Fitzgibbon J, Paschka P. The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukaemia. Hematol Oncol. 2010;28(1):13-19.
28. Hahn CN, Chong CE, Carmichael CL, et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet. 2011;43(10): 1012-1017.
29. Greif PA, Dufour A, Konstandin NP, et al. GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia. Blood. 2012;120(2): 395-403.
30. Tang JL, Hou HA, Chen CY, et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood. 2009;114(26):5352-5361.
31. Heuser M, Beutel G, Krauter J, et al. High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood. 2006;108(12): 3898-3905.
32. Garzon R, Volinia S, Liu CG, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 2008;111(6):3183-3189.
33. Byers RJ, Currie T, Tholouli E, Rodig SJ, Kutok JL. MSI2 protein expression predicts unfavorable outcome in acute myeloid leukemia. Blood. 2011; 118(10):2857-2867.
34. Care RS, Valk PJ, Goodeve AC, et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol. 2003;121(5):775-777.
35. Verhaak RG, Goudswaard CS, van Putten W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood. 2005; 106(12):3747-3754.
36. Wouters BJ, Löwenberg B, Erpelinck- Verschueren CA, van Putten WL, Valk PJ, Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood. 2009;113(13): 3088-3091.
37. Ribeiro AF, Pratcorona M, Erpelinck-Verschueren C, et al. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood. 2012;119(24):5824-5831.
38. Pratcorona M, Abbas S, Sanders MA, et al. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value. Haematologica. 2012;97(3):388-392.
39. Whitman SP, Liu S, Vukosavljevic T, et al. The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy. Blood. 2005;106(1): 345-352.
40. Ostler KR, Davis EM, Payne SL, et al. Cancer cells express aberrant DNMT3B transcripts encoding truncated proteins. Oncogene. 2007; 26(38):5553-5563.
41. Nakao M, Horiike S, Fukushima-Nakase Y, et al. Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/runt-related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome. Br J Haematol. 2004;125(6):709-719.
42. Bruserud Ø, Reikvam H, Fredly H, et al. Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation. Oncotarget. 2015; 6(5):2794-2811.
43. Marshall PA, Hernandez Z, Kaneko I, et al. Discovery of novel vitamin D receptor interacting proteins that modulate 1,25-dihydroxyvitamin D3 signaling. J Steroid Biochem Mol Biol. 2012; 132(1-2):147-159.
44. Minke KS, Staib P, Puetter A, et al. Small molecule inhibitors of WNT signaling effectively induce apoptosis in acute myeloid leukemia cells. Eur J Haematol. 2009;82(3):165-175.
45. Seba AWQ, Ming M, Qian Z. Growth inhibition of a myeloid leukemia cell line with 5q deletion by beta-catenin inhibition. Blood. 2012;120. [Abstract 3608].
46. Knappskog S, Myklebust LM, Busch C, et al. RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancer. Ann Oncol. 2011;22(10):2208-2215.
47. Ysebaert L, Chicanne G, Demur C, et al. Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. Leukemia. 2006; 20(7):1211-1216.
48. Metzeler KH, Heilmeier B, Edmaier KE, et al. High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia. Blood. 2012;120(10):2118-2126.
49. Aras S, Pak O, Sommer N, et al. Oxygen-dependent expression of cytochrome c oxidase subunit 4-2 gene expression is mediated by transcription factors RBPJ, CXXC5 and CHCHD2. Nucleic Acids Res. 2013;41(4):2255-2266.
50. Ko M, An J, Bandukwala HS, et al. Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX. Nature. 2013; 497(7447):122-126.